Research Study

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04965842 MONOTHERAPY IN SUBJECTS AGED 12 YEARS AND OLDER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Principal Investigator 
Vincent C. Ho

Overview

Body Locations and Systems 
Dermatitis
ClinicalTrials.gov# 
NCT03575871
Status 
Recruiting
Study Start/End 
Feb 26, 2019 to Aug 13, 2019
Locations 
Vancouver General Hospital
Name/Title 
Grace Mak, Study Coordinator
Phone 
604-875-5296
Email Address 
grace.mak@ubc.ca
Purpose of Study 

The purpose of this study is to evaluate the efficacy and safety of two dosage strengths of PF-04965842 (100 mg and 200 mg taken orally once daily) relative to placebo over 12 weeks of study participation.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.